DBV Technologies (NASDAQ:DBVT) Now Covered by StockNews.com

Analysts at StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a note issued to investors on Monday. The firm set a “hold” rating on the stock.

Several other analysts have also recently commented on DBVT. JMP Securities restated a “market outperform” rating and issued a $5.00 target price on shares of DBV Technologies in a research note on Tuesday, September 24th. HC Wainwright reiterated a “buy” rating and issued a $5.00 price target on shares of DBV Technologies in a report on Thursday, August 1st.

DBV Technologies Price Performance

Shares of NASDAQ:DBVT opened at $0.70 on Monday. DBV Technologies has a 1-year low of $0.50 and a 1-year high of $2.28. The stock has a market cap of $67.55 million, a P/E ratio of -0.83 and a beta of 0.67. The firm has a fifty day moving average price of $0.78 and a 200 day moving average price of $0.96.

DBV Technologies (NASDAQ:DBVT) last released its earnings results on Tuesday, July 30th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.08). DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. The firm had revenue of $1.16 million during the quarter, compared to analyst estimates of $1.42 million. During the same quarter last year, the business posted ($0.26) EPS. Sell-side analysts expect that DBV Technologies will post -1.43 EPS for the current fiscal year.

Hedge Funds Weigh In On DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. raised its holdings in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,568,909 shares of the company’s stock after acquiring an additional 327,345 shares during the quarter. DBV Technologies makes up 0.2% of Yiheng Capital Management L.P.’s investment portfolio, making the stock its 15th largest position. Yiheng Capital Management L.P. owned approximately 2.89% of DBV Technologies worth $4,172,000 as of its most recent SEC filing. 71.74% of the stock is currently owned by institutional investors and hedge funds.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.